# Phase 3 Study to Compare the Efficacy and Safety of Gemigliptin and Vildagliptin as Add-on Therapy to Metformin in People With Type 2 Diabetes Inadequately Controlled With Metformin

> **NCT02343926** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 443 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** GEMIGLIPTIN LS15-0444
- **DRUG:** vildagliptin
- **DRUG:** metformin

## Key facts

- **NCT ID:** NCT02343926
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2016-04
- **Final completion:** 2016-04
- **Target enrollment:** 443 (ACTUAL)
- **Last updated:** 2016-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02343926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02343926, "Phase 3 Study to Compare the Efficacy and Safety of Gemigliptin and Vildagliptin as Add-on Therapy to Metformin in People With Type 2 Diabetes Inadequately Controlled With Metformin". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT02343926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*